LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 19 of 497
Next
>>
>
451 to 475 of 12420 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Relative Growth Rate After Treatment
BT-20	CP724714	0.12	uM	LJP5	1	A11	72	hr	1097	3555	3769	0.9431	0.9197
BT-20	CP724714	0.12	uM	LJP5	2	A11	72	hr	1097	3608	3769	0.9572	0.9396
BT-20	CP724714	0.12	uM	LJP5	3	A11	72	hr	1097	3813	3769	1.0115	1.0163
BT-20	CP466722	0.12	uM	LJP5	1	I11	72	hr	1097	4211	3769	1.1171	1.1652
BT-20	CP466722	0.12	uM	LJP5	2	I11	72	hr	1097	3735	3769	0.9908	0.9871
BT-20	CP466722	0.12	uM	LJP5	3	I11	72	hr	1097	4200	3769	1.1142	1.1611
BT-20	Crizotinib	0.12	uM	LJP5	1	A23	72	hr	1097	3402	3769	0.9025	0.8625
BT-20	Crizotinib	0.12	uM	LJP5	2	A23	72	hr	1097	3762	3769	0.9980	0.9972
BT-20	Crizotinib	0.12	uM	LJP5	3	A23	72	hr	1097	3525	3769	0.9351	0.9085
BT-20	Momelotinib	0.12	uM	LJP5	1	P11	72	hr	1097	3229	3769	0.8566	0.7977
BT-20	Momelotinib	0.12	uM	LJP5	2	P11	72	hr	1097	3888	3769	1.0314	1.0443
BT-20	Momelotinib	0.12	uM	LJP5	3	P11	72	hr	1097	3313	3769	0.8789	0.8292
BT-20	Dasatinib	0.12	uM	LJP5	1	D05	72	hr	1097	2183	3769	0.5791	0.4063
BT-20	Dasatinib	0.12	uM	LJP5	2	D05	72	hr	1097	2080	3769	0.5518	0.3678
BT-20	Dasatinib	0.12	uM	LJP5	3	D05	72	hr	1097	2656	3769	0.7046	0.5833
BT-20	Dasatinib	0.12	uM	LJP6	1	I05	72	hr	1097	1486	3769	0.3942	0.1455
BT-20	Dasatinib	0.12	uM	LJP6	2	I05	72	hr	1097	1531	3769	0.4062	0.1623
BT-20	Dasatinib	0.12	uM	LJP6	3	I05	72	hr	1097	1350	3769	0.3581	0.0946
BT-20	Dovitinib	0.12	uM	LJP5	1	E23	72	hr	1097	2387	3769	0.6332	0.4826
BT-20	Dovitinib	0.12	uM	LJP5	2	E23	72	hr	1097	2689	3769	0.7134	0.5957
BT-20	Dovitinib	0.12	uM	LJP5	3	E23	72	hr	1097	2562	3769	0.6797	0.5481
BT-20	Enzastaurin	0.12	uM	LJP5	1	D17	72	hr	1097	3936	3769	1.0442	1.0623
BT-20	Enzastaurin	0.12	uM	LJP5	2	D17	72	hr	1097	3887	3769	1.0312	1.0440
BT-20	Enzastaurin	0.12	uM	LJP5	3	D17	72	hr	1097	4303	3769	1.1415	1.1996
BT-20	Erlotinib	0.12	uM	LJP5	1	M23	72	hr	1097	3137	3769	0.8322	0.7633

|<
<<
Previous
Page 19 of 497
Next
>>
>
451 to 475 of 12420 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)